Lexicon inks a $145M pact with Ipsen; Boehringer launches PhIII nintedanib study for colorectal cancer;

@FierceBiotech: Viamet drops IPO, spins out cancer drug as ex-Elan chief funds $60M round. More | Follow @FierceBiotech

@JohnCFierce: Kelly Martin (Elan) is ba-a-a-ack. Viamet drops IPO, spins out cancer drug as ex-Elan chief funds $60M round. | Follow @JohnCFierce

@DamianFierce: Have to applaud $ABBV's vanity url game, securing HepC.com right in $GILD's face. Article | Follow @DamianFierce

@EmilyMFierce: $JNJ gives the Ebola vaccine push a $200M boost. News | Follow @EmilyMFierce

> Texas-based Lexicon Pharmaceuticals is picking up a $23 million upfront from its new licensing pact with France's Ipsen covering the ex-U.S. and Japan rights to the late-stage drug telotristat etiprate for carcinoid syndrome. The deal package is worth up to $145 million. "Ipsen is a leader in the treatment of carcinoid syndrome and neuroendocrine tumors with Somatuline (lanreotide)," says Lexicon CEO Lonnel Coats. "Lexicon will benefit commercially from Ipsen's substantial market presence in Europe and other countries in the licensed territory, and will benefit globally from coordination with Ipsen on medical and scientific matters. Release

> Boehringer Ingelheim has launched a Phase III study of nintedanib for colorectal cancer. Release

Medical Device News

@FierceMedDev: Siemens in talks to sell hearing aids biz for $2.6B+. More | Follow @FierceMedDev

@VarunSaxena2: GSK exec stresses need to move away from 'fragmented' approach to drug delivery. Story | Follow @VarunSaxena2

@EmilyWFierce:  Roche plots $3.2B overhaul at Basel HQ, joining parade of Big Pharma building projects. Article | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain | Follow @MichaelGFierce

> AirStrip, IBM partner to create acute care mobile monitoring. More

> Sorin invests $20M in implantable respiratory device startup Respicardia. Article

> Boston Scientific upbeat on Watchman approval for 1H15, pegs 'conservative' $500M market. News

Pharma News

@FiercePharma: Top-read special report Monday: The top 10 most expensive drugs of 2013. More | Follow @FiercePharma

@EricPFierce: ICYMI: India's Ascend sold laxatives to urea creams the #FDA never approved. It's now headed for incineration. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF. Article | Follow @CarlyHFierce

> GlaxoSmithKline sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts. More

> Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up. Story

> GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots. News

Drug Delivery News

> Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain. News

> Highland pulls in $25M for night-dosed morning ADHD treatment. Story

> Encapsulation of fecal matter achieved for treatment of infected colons. More

> Sanofi leads $11M Series A round for needle-free delivery company. Report

> GSK exec stresses need to move away from 'fragmented' approach to drug delivery. Article

Diagnostics News

> Quest and LabCorp won't accept blood samples from suspected Ebola patients. Story

> Xagenic names CEO to help commercialize lab-free molecular Dx tech. Report

> Celgene takes equity stake in Sequenta and its precise Dx tech. News

> BioMérieux subsidiary nails Medicare coverage for breast cancer molecular test. Article

> Virginia Tech finds possible biomarker for rare immunodeficiency condition. Item

Pharma Marketing News

> Is your DTC campaign working? New program tracks viewers from TV to pharmacy. Report

> Cancer survivor's petition pleads with Roche for lower Kadcyla price. News

> GlaxoSmithKline puts emerging markets chief Hussain in charge of global pharma ops. More

> Advair sales slide triggers another $1.6 billion in cost cuts at GlaxoSmithKline. Article

> Novartis recruits Nick Cannon for double-whammy flu campaign. Report

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.